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Zusammenfassung
Hintergrund: Verlaufsmessungen von CA-19-9-Spiegeln haben eine
Aussagekraft bezüglich der Ansprechrate und Überlebenszeit von
Patienten die wegen eines Pankreaskarzinoms operiert, bestrahlt
oder chemotherapiert werden. In der vorliegenden Arbeit wurden
prospektiv CA-19-9-Spiegel von Patienten mit lokal fortgeschritte-
nem oder metastasiertem Pankreaskarzinom untersucht, die mit
einer Kombinationschemotherapie bestehend aus Gemcitabin und
Cisplatin behandelt wurden. Patienten und Methoden: Insgesamt
wurden 87 Patienten (m/w = 26/61; Stadium III/IV = 24/63) in die Stu-
die eingeschlossen. Die Tumormarkerspiegel wurden unmittelbar
vor Beginn der Chemotherapie, und im Verlauf vor jedem weiteren
Chemotherapiezyklus bestimmt. Die Chemotherapie bestand aus
Gemcitabine 1000 mg/m2 (Tag 1, 8, 15) und Cisplatin 50 mg/m2 (Tag
1, 15), und wurde an Tag 28 wiederholt. Ergebnisse: Von 87 einge-
brachten Patienten hatten 77 initial erhöhte CA-19-9-Spiegel (88,5%)
und wurden daher weiter ausgewertet. Nach Bildgebungskriterien
(CT-Befund) erreichten 4 Patienten eine komplette Remission (5,2%)
und 11 (14,3%) eine partielle Remission, so dass eine Gesamtan-
sprechrate von 19,5% resultiert. Von insgesamt 77 Patienten mit in-
itial erhöhten CA-19-9-Spiegeln erfüllten 43 (55,8%) das Kriterium
eines «CA-19-9-Responders» (definiert als Abfall des CA 19-9 ≥50%
innerhalb der ersten 2 Monate nach Beginn der Behandlung). Bis
auf einen Patienten erfüllten alle Patienten die nach Bildgebungskri-
terien angesprochen hatten (n = 14) auch das Kriterium eines «CA-
19-9-Responders». Interessanterweise wurden unter den Patienten
die nach Bildgebungskriterien nicht angesprochen hatten (SD/PD),
dennoch 29 Patienten als «CA-19-9-Responder» klassifiziert. Unab-
hängig vom CT-Befund lebten «CA-19-9-Responder» signifikant län-
ger als «CA-19-9-Non-Responder» (295 Tage; 95%-CI: 285–445 vs.
174 Tage; 95%-CI: 134–198; p = 0,022). Schlussfolgerung: CA-19-9-
Spiegel im Verlauf einer Chemotherapie mit Gemcitabin und Cis-
platin erlauben bei Patienten mit Pankreaskarzinom neben einer frü-
hen Beurteilung des Ansprechens auf die Chemotherapie auch eine
Prognose bezüglich der Überlebenszeit.
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Summary
Background: Serial kinetics of serum CA 19-9 levels have been re-
ported to reflect response and survival in patients with pancreatic
cancer undergoing surgery, radiotherapy, and chemotherapy. We
prospectively studied serial kinetics of serum CA 19-9 levels of pa-
tients with locally advanced or metastatic disease treated with gem-
citabine and cisplatin. Patients and Methods: Enrolled in the study
were 87 patients (female/male = 26/61; stage III/IV disease = 24/63).
Patients received gemcitabine 1,000 mg/m2 on days 1, 8, and 15
plus cisplatin 50 mg/m2 on days 1 and 15, every 4 weeks. Serum
samples were collected at the onset of chemotherapy and before
the start of a new treatment cycle (day 28). Results: 77 of 87 patients
(88.5%) with initially elevated CA 19-9 levels were included for eval-
uation. According to imaging criteria, 4 (5.2%) achieved a complete
remission and 11 (14.3%) achieved partial remission, yielding an
overall response rate of 19.5%. 43 (55.8%) patients were CA 19-9
responders, defined by a ≥50% decrease in CA 19-9 serum levels
within 2 months after treatment initiation. Except for one, all pa-
tients who had responded by imaging criteria (n = 14) fulfilled the
criterion of a CA 19-9 responder. Despite being characterized as
non-responders by CT-imaging criteria (stable/progressive disease),
29 patients were classified as CA 19-9 responders (positive predic-
tive value 32.5%). Independent of the response evaluation by CT,
CA 19-9 responders survived significantly longer than CA 19-9 non-
responders (295 d; 95% CI: 285–445 vs. 174 d; 95% CI: 134–198; p =
0.022). Conclusion: CA 19-9 kinetics in serum serve as an early and
reliable indicator of response and help to predict survival in patients
with advanced pancreatic cancer receiving effective treatment with
gemcitabine and cisplatin. 
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Introduction
Pancreatic cancer is currently the fifth most frequent tumor-
related cause of death. Unresectable pancreatic cancer has a
dismal prognosis, and 5-year survival is generally less than 5%
[1]. Therapeutic efforts at tumor stages III and IV are essen-
tially directed toward palliation, because a cure cannot be
achieved in most patients. Since the introduction of gem-
citabine, which is superior to 5-FU (5-fluorouracil) regarding
clinical benefit, response, and survival, great efforts have been
undertaken to evaluate the impact of chemotherapy by meth-
ods other than imaging of tumor volume [1–8].
Response evaluation by standard imaging procedures is par-
ticularly complicated by limited differentiation of tumor from
normal surrounding tissue, which is partly explained by
desmoplastic and local inflammatory reactions induced by the
tumor [3]. One approach has been to measure clinical benefit
response, which is a composite endpoint consisting of pain,
analgesic consumption, performance status, and weight, but
the value of this parameter as a convenient and reliable surro-
gate endpoint of response still remains debatable [9].
In search for a quick and objective response evaluation, CA
19-9 kinetics have been analyzed in patients undergoing
chemotherapy of pancreatic carcinoma. CA 19-9 is a sialylated
Lewis antigen known as a sensitive marker in pancreatic can-
cer [10–17]. Although it is generally agreed that tumor mark-
ers are inadequate screening tools for the diagnosis of cancer
[12, 18], they may well serve to guide therapy of proven cancer
disease. CA 19-9 has been used as a prognostic indicator of
disease status during follow-up evaluations after surgery,
radio-, or chemotherapy [17]. There is no agreement, howev-
er, to which extent CA 19-9 can be used as a surrogate end-
point for response evaluation during chemotherapy of ad-
vanced or metastatic disease. Moreover, a clear definition of
CA 19-9 response has not been established. In previous stud-
ies CA 19-9 response was defined as a decrease from baseline
ranging between 15 and 50% [16, 19, 20]. The goal of this
study was to evaluate the value of CA 19-9 kinetics as a re-
sponse parameter complementary to conventional radiologi-
cal imaging and to define its prognostic importance during in-
tensive chemotherapy with gemcitabine and cisplatin. 
Patients and Methods
Patient Selection
The current analysis includes the data of two previously published clinical
trials [6, 8]. Inclusion criteria for the present study were histologically or
cytologically proven advanced or metastatic pancreatic cancer; bidimen-
sionally measurable disease; relapsing disease or disease not responding
to initial radiochemotherapy; Karnofsky performance status of ≥70%; age
18–70 years; and anticipated survival of at least 12 weeks. In addition, car-
diac, hepatic, renal, and hematological function had to be adequate. Pa-
tients were excluded for active infection; inadequate renal or cardiac func-
tion; and a history of a second malignancy other than resected basal cell
and/or squamous cell carcinoma of the skin. All patients gave written in-
formed consent, and the local ethics committee approved the treatment
protocol.
Treatment Regimen
Initially 34 patients received a combination chemotherapy consisting of
gemcitabine 1,000 mg/m2 on days 1, 8, and 15, and cisplatin 50 mg/m2 on
days 1 and 15. To improve treatment tolerability and to reduce toxicity,
the regimen was subsequently modified in a second trial by omitting the
day-8 gemcitabine dose in 43 patients. Treatment was administered in 4-
week cycles, and continued until disease progression or occurrence of se-
vere side effects.
Baseline and Treatment Assessments
Standard evaluation by history, physical examination, and routine labora-
tory tests was performed before each treatment. Imaging studies using
computerized tomography (CT) were performed after every 2 cycles of
treatment; only bidimensionally measurable lesions were used for these
response evaluations. For all patients, tumor lesions were measured by
CT within 14 days of entry into the study and subsequently after every 2
cycles of treatment. The criterion assessing the clinical response was the
best response at any time during treatment and follow-up. Patient re-
sponse was assessed by standard WHO criteria [21]. Drug administration,
performance status, toxicity, and adverse events were recorded after every
cycle of treatment. Toxicity was graded according to the National Cancer
Institute Common Toxicity Criteria [22].
Determination of CA 19-9 Serum Concentrations
CA 19-9 serum concentrations were prospectively determined by an auto-
mated enzyme immunoassay based on the sandwich principle (Enzy-
mun®, Boehringer Mannheim, ES 700, Germany). Serum samples were
routinely collected at the onset of chemotherapy and before the start of
any new treatment cycle (day 28). CA 19-9 response was defined as a
≥50% decrease from pretreatment levels within 2 months after the start of
treatment and was evaluated according to the criteria of Ishii et al. [16]. If
another threshold was chosen for defining CA 19-9 response this is indi-
cated in the tables. 
To be considered evaluable for response, patients had to complete at least
2 cycles of chemotherapy and required elevated CA 19-9 levels above the
normal range at baseline. According to previous studies evaluating CA
19-9 in healthy volunteers, a cut-off value of 32 U/ml, reflecting the 95th
percentile, was used as the upper limit of the normal (ULN) range [18]. 
Statistical Evaluation
Survival times were measured from the date of the start of treatment to
the date of death from any cause. The probability of survival was estimat-
ed by Kaplan-Meier analysis [23]. Differences between patient groups in
survival and differences between other parameters were calculated using
the log-rank or t-test. Changes in marker expression were compared with
CT-scans. These changes were expressed in terms of sensitivity, specificity,
and positive or negative predictive value. The following definitions apply:
Sensitivity = true positive / (true positive + false negative) × 100%,
Specificity = true negative / (true negative + false positive) × 100%,
Positive predictive value (PPV) = true positive / (true positive + false pos-
itive) × 100%,
Negative predictive value (NPV) = true negative / (true negative + false
negative) × 100%.
Results
Patient Characteristics
Between September 1994 and January 2001, 87 patients, 61
males and 26 females, with advanced pancreatic cancer were
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recruited. The present analyses hereby included data of two
previously published trials. Detailed informations about pa-
tient characteristics are shown in table 1. 
Response Evaluation by CT-Imaging and Survival
Of the 77 patients evaluable for response, 4 (5.2%) achieved a
complete remission (CR) and 11 (14.3%) achieved partial re-
mission (PR), yielding an overall tumor response rate of
19.5%. 35 (45.5%) patients achieved stable disease (SD), and
a further 27 (35.1%) patients showed progressive disease
(PD) during treatment. The median survival of the responder
group (CR+PR, median 363 days; 95% CI: 284–705) was sig-
nificantly longer than that of the non-responder group
(SD+PD, median 203 days; 95% CI: 194–278; p = 0.03, log
rank test). 
CA 19-9 Serum Concentrations and Response by Radiologic
Imaging
The relationship between serum CA 19-9 changes and re-
sponse to chemotherapy as evaluated by CT scan is shown in
detail in table 2, informations on sensitivity and specificity of
CA 19-9 response in relation to CT response are given in table
3. All 4 patients who achieved CR showed a ≥50% decline
from baseline in CA 19-9 levels within 2 months of the start of
treatment, and were thus considered CA 19-9 responders.
Among the 11 patients who achieved PR, 10 were considered
CA 19-9 responders. For the 35 patients who achieved SD, 21
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Table 1. Patient characteristics
Patients enrolled, n 87 
Male/female, n (%) 61/26 (70.1/29.9) 
Age, years   
Median 59 
Range 33–72 
Karnofsky performance status, %  
Median 80
Range 70–100 
Disease stage, n (%)  
Stage III (T1–4, N1, M0) 24 (27.6) 
Stage IV (T1–4, N0–1, M1) 63 (72.4) 
Patients without elevated CA 19-9 levels (n =10) 
Elevated bilirubin serum levels, n (%)  
≥1.1 mg/dl 4 (40) 
≥3.0 mg/dl 0 
Patients with elevated CA 19-9 levels (n =77) 
Male/female, n (%) 53/24 (68.8/31.2) 
Disease stage, n (%)  
Stage III (T1–4, N1, M0) 16 (20.8) 
Stage IV (T1–4, N0–1, M1) 61 (79.2) 
Median CA 19-9 (range), U/ml 953 (44–742,398) 
Stage III disease (T1–4, N1, M0) 344 (53–5001) 
Stage IV disease (T1–4, N0–1, M1) 1,911 (44–742,398)*
Elevated bilirubin serum levels, n (%)  
≥1.1 mg/dl 17 (22.1) 
≥3.0 mg/dla 7 (9.1) 
Liver metastases, n (%) 56 (72.7) 
Prior therapy, n (%)  
No prior therapy 59 (76.6) 
Surgery of curative intent 14 (18.2) 
Surgery of palliative intent 4 (5.2) 
Radio-/chemotherapy (5-fluorouracil-based), 
n (%) 5 (6.5) 
*p < 0.001 for the difference between median CA 19-9 values of patients
with disease stages III and IV.
aIn 3 patients, bilirubin decreased to normal range after stent implanta-
tion. 
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Figure 1. Probability of survival of CA 19-9 responders (solid line) and
non-responders (dashed line). 
+: Censored data.
{: according to the criterion by Ishii et al. [21]: CA 19-9 responder: medi-
an 295 days (range: 64–1,147; 95% CI: 285–445 days); CA 19-9 non-re-
sponder: median 174 days (range: 17–411; 95% CI: 134–198 days) p =
0.022 (log rank).
∆: according to the criterion by Gogas et al. [25]: CA 19-9 responder: me-
dian 270 days (range: 64–1,147; 95% CI: 271–409 days); CA 19-9 non-re-
sponder: median 144 days (range: 17–743; 95% CI: 111–225 days) p =
0.017 (log rank).
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Figure 2. Probability of survival of CA 19-9 responders according to Ishii
[21] (solid line) and non-responders (dashed line) of patients with pro-
gressive disease by CT imaging criteria (n = 27); +: Censored data.
CA 19-9 responder: median 247 days (range: 64–683; 95% CI: 135–475
days); CA 19-9 non-responder: median 142 days (range: 43–256; 95% CI:
109–175 days) p = 0.04 (log rank).
qualified as CA 19-9 responders, and the CA 19-9 levels for
most patients who progressed increased above baseline levels.
(15/27). However, 12 of the 27 patients in this group showed a
biochemical response, characterized by decreases in CA 19-9
levels (8 of them qualified as CA 19-9 responders) despite
tumor progression documented by CT scan. 
CA 19-9 Response and Survival
To identify the best model predicting tumor response we eval-
uated the CA 19-9 response using thresholds of 15% and 50%.
According to the response criteria reported by Ishii et al. [16]
(CA 19-9 decrease ≥50%) we identified 43 patients qualifying
as CA 19-9 responders and 34 patients as CA 19-9 non-re-
sponders. CA 19-9 responders survived significantly longer
than CA 19-9 non-responders (p = 0.022) (fig. 1). The median
survival of CA 19-9 responders was 295 days (95% CI:
285–445), while CA 19-9 non-responders had a survival of 174
days (95% CI: 134–198; p = 0.022). Using a cut-off for CA 19-
9 response as defined by Gogas et al. [20] (CA 19-9 decrease
≥15%) we observed 48 CA 19-9 responders with a median sur-
vival of 270 days (95% CI: 271–409) and 29 non-responders
with a median survival of 144 days (95% CI: 111–225) (p =
0.017). As demonstrated in figure 2, a significant difference of
survival was not detected between the two models (p > 0.05). 
Patients identified as having progressive disease according to
CT imaging criteria showed a median survival of 188 days
(95% CI: 109–321 days). Dividing this group into patients who
did and did not respond, according to CA 19-9 response, CA
19-9 responders (response criteria by Ishii) had a significantly
longer median survival than did CA 19-9 non-responders (247
days (95% CI: 135–475) vs. 142 days (95% CI: 109–175); p =
0.04) (fig. 2). 
Discussion
In this study, sequential CA 19-9 values were determined in
patients with advanced pancreatic cancer treated with a com-
bination of gemcitabine and cisplatin [6, 8]. The therapeutic
efficacy of this combination treatment is supported by a 1-year
survival rate of 38%. Burris and coworkes reported a 1-year
survival rate of 18% for patients treated with single-agent
gemcitabine, while a significantly lower rate of 2% was ob-
tained with 5-FU [4]. 
Reliable parameters of treatment efficacy are necessary tools
to guide antitumor treatment. In pancreatic cancer, however,
timeliness and reliability of response evaluation are difficult to
achieve using conventional imaging procedures. Inclusion of
desmoplastic tissue into the baseline tumor volume may cause
an underestimation of tumor reduction during therapy, while
inclusion of surrounding inflammatory tissue could result in
an overestimation of response [3]. Although CT is one of the
most reliable modalities for response evaluation, the correla-
tion of CT measurements of tumor volume and that of resect-
ed specimens was shown to be limited [16].
In search for an objective and easily obtained endpoint during
evaluation of chemotherapeutic efficacy, we prospectively
measured CA 19-9 serum concentrations in patients undergo-
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CT scan responder  CT scan non-responder 
Complete response Partial response Stable disease Progressive disease 
Patients, n 4 11 35 27 
Baseline CA 19-9 level, U/ml     
Median  1,747 2,097 486 1,911 
Range  134–3,318 51–21,573 53–102,000 44–742,398 
CA 19-9 changes, n (%)     
Overall decrease (n = 58) 4 (100) 11 (100) 31 (89) 12 (44) 
Decrease to <32U/ml (n = 11) 3 (75) 3 (27) 4 (11) 1 (4) 
Increase from baseline (n = 19) 0 (0) 0 (0) 4 (11) 15 (56) 
CA 19-9 response (≥50%)a
CA 19-9 responder (n = 43) 4 (100) 10 (91) 21 (60) 8 (30) 
CA 19-9 non-responder (n = 34) 0 (0) 1 (9) 14 (40) 19 (70) 
CA 19-9 response (≥15%)b
CA 19-9 responder (n = 48) 4 (100) 10 (91) 23 (66) 11 (41) 
CA 19-9 non-responder (n = 29) 0 (0) 1 (9) 12 (34) 16 (59) 
a As defined by Ishii et al. [21].
b As defined by Gogas et al. [25].  
Table 2. CA 19-9
and response accor-
ding to imaging crite-
ria (n = 77)
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ing combination chemotherapy. In metastatic disease, the ab-
solute value of pretreatment CA 19-9 levels is not a prognostic
factor for survival due to a great interpatient variability [13].
This study, therefore, focused on the analysis of CA 19-9 ki-
netics rather than absolute values.
For a correct interpretation of CA 19-9 levels, several points
have to be taken into consideration: 
1. The range of normal CA 19-9 levels is rather broad. Stud-
ies in healthy volunteers demonstrated a median CA 19-9
concentration of 3.1 U/ml, while the 10-fold greater value
of 31.9 U/ml was equivalent to the 95th percentile. 
2. Elevated CA 19-9 serum concentration levels occur in
1–4% of benign diseases, such as cholecystitis, obstructive
jaundice, cholelithiasis, cholangitis, hepatitis, and liver cir-
rhosis [12]. 
3. Patients lacking the Lewis-antigen glycosyltransferase
(Lewisa-/b-) are unable to produce CA 19-9. This deficiency
is observed in 7–10% of the general population, who ac-
cordingly will not show CA 19-9 elevations in the course of
pancreatic cancer [12].
A previous analysis of Halm and co-workers [19] indicated
that CA 19-9 response, namely a CA 19-9 decrease by ≥20%
within 2 months after start of treatment, might be the
strongest independent predictor of survival. Based on the re-
sponse definition of Gogas and co-workers (CA 19-9 decrease
by ≥15%), CA 19-9 responders of the present study showed a
significantly longer survival (270 days; 95% CI: 271–409) than
non-responders (144 days; 95% CI: 111–225; p = 0.017). By
comparison, when the response criteria established by Ishii
and coworkers [16] were used (CA 19-9 decrease by ≥50%
from baseline) CA 19-9 responders survived for a median of
295 days (95% CI: 285–445), while non-responders had a sur-
vival of 174 days (95% CI: 134–198; p = 0.022). These results
suggest that different cut-offs of CA 19-9 decrease (≥15% vs.
≥50%) occurring within the same frame of treatment will yield
comparable results since the impact on survival using the two
models was not significantly different (p > 0.05, figure 1).
In a further step, CA 19-9 kinetics were compared to response
evaluation by radiographic imaging. With one exception, all
patients who achieved a remission according to imaging were
also CA 19-9 responders. This observation indicates that re-
sponses defined by imaging are closely paralleled and sup-
ported by CA 19-9 kinetics. On the other hand, 60% (21/35) of
patients with SD, and 30% (8/27) of patients diagnosed with
progression by imaging criteria were categorized as CA 19-9
responders. It appears that treatment effects are more rapidly
reflected by changes of biological parameters such as tumor
markers, while changes of tumor volume as analyzed by imag-
ing procedures occur at a much slower rate.
Of 27 patients identified as having progressive disease by CT
imaging 12 showed a biochemical response with regard to CA
19-9 levels (fig. 2). This observation was not completely unex-
pected because tumor marker decreases in apparently pro-
gressing patients have also been noted by others [16, 19]. The
importance of this finding is best demonstrated by an evalua-
tion of survival. Even among patients with progressive disease
according to CT evaluation, CA 19-9 responders lived signifi-
cantly longer than non-responders (247 vs. 142 days; p = 0.04).
The most probable explanation resides in the known difficulty
to adequately assess the tumor size of pancreatic cancers by
radiological imaging [16, 19]. 
In conclusion, CT imaging still remains the gold-standard of
response evaluation in advanced and metastatic pancreatic
cancer. But it may be concluded that CA 19-9 kinetics are an
additional and helpful parameter for evaluating the response
and predicting survival in patients undergoing cytotoxic treat-
ment for metastatic pancreatic cancer.
Sensitivity 93.3% 
Specifity 53.2% 
Positive predictive value 32.5% 
Negative predictive value 97.1% 
Table 3. CA 19-9 
response and CT 
findings
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